<DOC>
	<DOCNO>NCT00002352</DOCNO>
	<brief_summary>The purpose study see lobucavir safe effective treatment cytomegalovirus patient AIDS .</brief_summary>
	<brief_title>A Study Lobucavir Patients With AIDS</brief_title>
	<detailed_description>Patients receive 1 2 dos lobucavir 28 day , 2 week follow-up . Weekly clinic visit require .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Lobucavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine . TMP / SMX . Isoniazid . Dapsone . Fluconazole . Ketoconazole . Rifabutin . Fluoxetine HCl . Acetaminophen . Antacids . Metamucil . Multivitamins . Other drug approval sponsor . Patients must : AIDS . CD4 count &lt; 200 cells/mm3 . Cytomegalovirus ( CMV ) viruria virosemenia . No evidence intraocular CMV . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Acute chronic cardiovascular , pulmonary , renal , hepatic , pancreatic , hematologic , endocrine , neurological , unstable illness . Inability take oral medication . Allergy nucleoside analog . Diarrheal illness . Poor venous access . Positive test drug abuse . Any condition would render patient unsuitable study . Patients follow prior condition exclude : History pancreatitis . Recent diarrheal illness . History weight loss . Acute serious illness within 4 week prior study entry . Prior Medication : Excluded within 4 week prior study entry : Erythropoietin . Any agent antiCMV activity . Other investigational agent . Prior Treatment : Excluded within 4 week prior study entry : Surgery . Blood transfusion . Drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>